VIMTALABSNSE28 April 2025

Vimta Labs Limited has informed the Exchange about Investor Presentation

Vimta Labs Limited

Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657

VLL\SE\007\2025 26 Date: 28.04.2025

B S E Limited, P J Towers, Dalal Street, Mumbai: 400001. Scrip Code No.524394

VimLa

Driven by Quality. Inspired by Science.

Asst Vice President, National Stock Exchange of India limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E, Mumbai 400051. Trading Symbol: VIMTALABS

Dear Sir Madam,

Sub:

Investor Presentation —Q4 results — FY 2024-25

Pursuant to provisions of Regulation Requirements Regulations, 2015 (the Investor Presentation.

30 of the SEBI (Listing Obligations and Disclosure “Listing Regulations”) we are enclosing herewith the

Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., httpsi/vimta.comlinvestor-presentatio

This is for your information and necessary records.

For VIMTA LABS LIMITED

Sujani Vasireddi Company Secretary

Attachments: as above.

Life Sciences Campus, #5, MN Science & Technology Park, Genome Valley, Shamirpet, Hyderabad -500 101, Telangana, India T: +91 40 6740 4040 E: mdoffice@vimta.com URL : www.vimta.com CIN : L24110TG1990PLC011977

Vimta Labs Limited

Investor Presentation Q4 & FY25

Disclaimer

The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.

TTTTT TT CTTTTTTT

Q4 & FY25 Earnings

Company Overview

Industry Landscape

Our Competitive Advantage

Way Forward

Q4 & FY25 Earnings

Q4 & FY25 Highlights FY25 Business Updates Key Metrics: Q4 & FY25 Profit & Loss Statement Financial Track Record Shareholding Pattern

Q4 FY25 Highlights

Rs 961 Mn

Total Income

Rs 347 Mn Margin 36.1% EBITDA

₹

Rs 8.22

EPS

Rs 39 Mn

CAPEX Outflow

Rs 250 Mn

PBT

Rs 183 Mn Margin 19.1% PAT

FY25 Highlights

Rs 3,482 Mn

Total Income

Rs 1262 Mn Margin 36.2% EBITDA

Rs 30.02

EPS

Rs 791 Mn

CAPEX Outflow

Rs 890 Mn

PBT

Rs 668 Mn Margin 19.2% PAT

0.02x

Debt to Equity Ratio

Rs 85 Mn (MTTTT 31TT 2025) Total Debt

Rs 329 Mn (MTTTT 31TT 2025)

Cash and Cash Equivalents

FY25 Business Updates

 Successful regulatory audits from various regulatory authorities: USFDA (Clinical GLP); European Medicines Agency (cGMP – human health and animal health); Turkey (cGMP); Kazakhastan (GCP), NGCMA (OECD-GLP) and CDSCO (GCP, Medical Devices).

 Forayed into Clinical trial services

 Food Division conferred with ‘Outstanding Laboratory Performance Award 2024‘ by CII for the 2nd

consecutive year.

 Business Transfer of CRL division to Thyrocare

 Relocated Pune food testing lab to Nashik with a view to be closer to agri produce regions.

 Capacity expansion: At Life Sciences Facility, added an additional ~200,000 sft of modern

laboratory spaces

 EMTAC is merged with Vimta: Scheme has been sanctioned by NCLT Hyderabad bench.

Key Metrics: Q4 FY25

Total Income (In ₹ Mn)

EBIDTA & EBIDTA Margin (In ₹ Mn, %)

PAT & PAT Margin (In ₹ Mn, %)

Basic EPS (In ₹)

EBIDTA

EBIDTA Margin

PAT

PAT Margin

31.4% YoY

31.9% YoY

36.0%

37.6%

36.1%

731

911

961

263

343

347

31.2% YoY

19.2 %

19.1 %

140

19.1 %

183

175

200

175

150

125

100

19 %

6.3

7.9

8.2

Q4FY24

Q3FY25

Q4FY25

Q4FY24

Q3FY25

Q4FY25

Q4FY24

Q3FY25

Q4FY25

Q4FY24

Q3FY25

Q4FY25

Key Metrics: FY25

Total Income (In ₹ Mn)

EBIDTA & EBIDTA Margin (In ₹ Mn, %)

PAT & PAT Margin (In ₹ Mn, %)

Basic EPS (In ₹)

EBIDTA

EBIDTA Margin

PAT

PAT Margin

19.1% YoY

29.1% YoY

33.4%

36.2%

2,923

FY24

3,482

FY25

977

FY24

1,262

FY25

725

700

675

650

625

600

575

550

525

500

475

450

425

400

375

350

325

300

275

250

225

200

175

150

125

100

36.8% YoY

16.7 %

488

FY24

20 %

19 %

18 %

17 %

16 %

15 %

19.2%

668

FY25

22.0

FY24

30.0

FY25

Financial Track Record

TOTAL INCOME (₹ Mn)

PROFITABILITY (₹ Mn)

1,837 2,115 2,797 3,216 2,923 3,482

11.2% CAGR

EBITDA & EBITDA Margin

PAT & PAT Margin

29%

31%

33%

36%

25%

18%

330

538

817

984

977 1,262

19%

17%

15% 15%

25.1% CAGR

10%

68 214 413 482 488 668

46.3% CAGR

FT20

FT21

FT22

FT23

FT24

FT25

FT20

FT21

FT22

FT23

FT24

FT25

FT20

FT21

FT22

FT23

FT24

FT25

Total Revenue

EBIDTA

EBIDTA Margin

PAT

PAT Margin

RoE (%)

RoCE (%)

Debt to Equity

Total Capex

BALANCE SHEET RATIOS

11%

18%

17%

15%

18%

15%

18%

25%

22%

19%

23%

FT20

FT21

FT22

FT23

FT24

FT25

FT20

FT21

FT22

FT23

FT24

FT25

0.2

0.1

0.0

0.16 0.16 0.08 0.05 0.06 0.02

166

357

450

492

763

791

FT20 FT21 FT22 FT23 FT24 FT25

a. b.

Financial numbers for the period FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business CAGR for the period FY20-FY25

Profit & Loss Statement

Particulars (₹ Mn)

Revenue from Operations

Other Income

Total Income

Material and Testing Costs

Cost of lab setup

Changes in inventories of work-in-progress

Employee benefits expense

Other expenses

Total Expenses

EBIDTA

EBIDTA (%)

Finance costs

Depreciation expense

Profit before tax

PBT (%)

Tax

Profit for the year

PAT (%)

Basic EPS (INR)

Q4 FY25

Q4 FY24

YoY (%)

Q3 FY25

QoQ(%)

944.4

16.4

960.8

181.6

0.2

0.0

272.6

159.6

614.1

346.8

36.1%

4.4

92.1

250.3

26.0%

67.1

183.2

19.1%

8.2

727.3

3.8

731.2

132.9

0.2

0.6

214.9

119.6

468.2

263.0

36.0%

5.3

78.4

179.4

24.5%

39.8

139.6

19.1%

6.3

899.0

12.0

911.0

204.0

2.0

0.0

234.0

128.0

568.0

343.0

37.6%

6.0

98.0

239.0

26.2%

64.0

175.0

19.2%

7.9

31.4%

31.9%

39.5%

31.2%

30.3%

5.5%

1.1%

4.7%

4.1%

FY25

3,439.8

42.4

3,482.2

710.2

4.3

0.0

970.2

535.7

2,220.3

1,261.9

36.2%

19.0

352.9

890.0

25.6%

222.5

667.5

19.2%

30.0

FY24

2,886.0

37.1

2,923.1

573.2

2.4

1.0

891.8

477.2

1,945.6

977.5

33.4%

21.0

331.4

625.0

21.4%

136.9

488.1

16.7%

22.0

YoY (%)

19.1%

29.1%

42.4%

36.8%

36.2%

Shareholding Pattern

Shareholding as on 31st March 2025

OTTTTT 58.2%

PTTTTTTTT 36.7%

DII 1.4%

FII 3.7%

Source: NSE & BSE

#Cash and Cash equivalents includes other bank balances

Share Information as on 31st March 2025

NSE Ticker

BSE Ticker

Market Cap (INR Cr)

% free-float

Free-float market cap (INR Cr)

Total Debt (INR Mn)

Cash & Cash Equivalents (INR Mn)

Shares Outstanding

3M ADTV (Shares)*

3M ADTV (INR Cr)*

Industry

VIMTALABS

524394

2,223.67

63.30%

1,407.57

329

2,22,34,512

1,89,397

18.62

TIC

Company Overview

Vimta at a Glance Our Journey Services Geographical Presence Management

Vimta at a Glance

Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing.

1,300+ Dedicated Multi-Disciplinary Team

10 Labs and Offices across India

40+ Years Of experience in CRTO industry

600,000+ Sq. Ft. of Ultra-modern lab spaces

90+ Successful Regulatory Audits

Our Journey

Infrastructure

People

Investment

Capabilities

Revenues

2024

600,000+ ft2

1300+

492 M

2015

400,000+ ft2

1000+

580 M

Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing

Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing

2006

1992

200,000+ ft2

600+

992 M

Clinical Research; Environment; Analytical Testing – Food & Pharma

50,000+ ft2

150+

85 M

Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research

1984

500 ft2

200,000

Minerals & ores; Metals; Rice bran oil testing

• •

Investment & Revenues in INR Investments depicted may have spread across more than the denoted year

3,216 M

1,073 M

542 M

16 M

156,000

Our offerings

Drug discovery and development services

Food & Agri Testing

Electronics & Electricals Testing

Environment Testing & Consultancy

1. Drug discovery and development services

Offerings

Industry

Pharma Analytical

Clinical Research

Preclinical Research

Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health.

Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals

Accreditations & Regulatory Approvals

DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey

CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs

OECD-GLP, CCSEA, DSIR, AAALAC

Services

 Wide range of analytical services  E&L studies  Stability testing  Method development  Validations  Genotoxic impurities  Elemental analysis  In vitro studies  Physical

studies

 Microbiology  Immunogenecity

 Characterization  Bioassays

Characterisation  Dissolution Testing

 BA/BE Studies  Bioanalytical  Clinical Trials (Phase I to IV)  Clinical End Point Studies  Claim Studies

 Comprehensive in vitro, ex vivo and in vivo studies  ADME, and PK  IND enabling packages (genetic toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).

 Chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, and carcinogenicity

 Biowaiver and alternative to animal studies  Ecotoxicology, environmental fate and metabolism

studies

2. Food & Agri Testing

Industry

No. of Locations

Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed

7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida)

Accreditations & Regulatory Approvals

• FSSAI, ISO 17025, BIS, APEDA, EIS, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing • Mumbai Lab is a National Food Laboratory, operated for FSSAI

Services

 Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all agri, food, food products, water

and beverages

 New product development support, validations  Shelf life assessments  Packaging material testing  Nutraceuticals testing, method validations  Animal feed analysis  Argo-chemical (crop sciences): support for research and development, method development, validation and testing for regulatory submissions in

India, Europe, South America, Japan, South East Asia

3. Electricals & Electronics Testing & Certification

Industry

No. of Laboratories

Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries

1 (Hyderabad)

Accreditations & Regulatory Approvals

ISO 17025, TEC BIS & NABCB (of Emtac Laboratories Pvt Ltd., fully owned subsidiary)

Services

 EMI/EMC testing  Radio Frequency testing  Environmental & reliability testing  Mechanical & electrical safety testing  Performance testing  Product Certification  CE marking

4. Environment Testing & Consultancy Services

Industry

No. of Locations

Accreditations & Regulatory Approvals

Services

Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc.

4 (Hyderabad, Chennai, Kolkata and Noida)

MoEF, ISO 17025, QCI/NABET, OSHAS 45000

 Post project monitoring  Industrial hygiene & Indoor air  Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans, Industrial Gas, VOC as per LEED and

EPA)

 Offshore monitoring  SIA & hydrogeological studies  EHS audits, Hazardous waste study, Life cycle assessment  Due diligence studies  Green audit, Metrological studies  Noise, air, traffic modelling etc.

Geographical Presence

Hyderabad (Headquarters)

Food

Pharma

Electronics & Electrical

Environment

Food

Environment

Electrical and Electronics

Hyderabad

Chennai

Noida

Kolkata

Hyderabad

Ahmedabad

Noida

Mumbai (NFL)

Nashik

Bengaluru

Nellore

Key Management Team

S P Vasireddi Executive Chairman

Harita Vasireddi Managing Director

Sreenivas Neerukonda Executive Director

Siva Kambhampati Chief Financial Officer

Harriman Vungal Executive Director - Operations

Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.

Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.

Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.

Her Core competencies include management & driving organizational adaptability and development, quality management systems, and risk management.

She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India

Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal- oriented performance.

an MBA Systems,

He holds Information Oklahoma, University, India.

USA;

B.Pharm,

in Management of Nagpur

University

Siva is a seasoned finance professional with a strong academic foundation. He is a CA and secured 63rd rank in cost accountancy. With over 16 years on experience in the engineering and pharmaceutical industries, he brings diverse expertise in strategic financial planning & management, product costing & pricing, and treasury management.

He has previously worked at Artson engineering Ltd. (A TATA Enterprise), Hyderabad as a CFO.

Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.

He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.

He holds D. Tech in Electronics from Toronto, Canada.

Industry Landscape

Market Opportunity Factors Driving Industry Growth

Markets Opportunity

a b o G

Pharmaceutical & Biopharmaceuticals

Preclinical

Food Testing

Environment Testing

Electronics Testing

957.6

127.3

40.5

20.2

) n B D S U

(

405.5

76.6

19.5

11.1

13.4

6.8

2020 | 2028

2023 | 2028

2022 | 2032

2022 | 2030

2021 | 2031

Markets Opportunity

Pharmaceutical & Biopharmaceuticals

130

n a d n I

) n B D S U

(

Preclinical

Food Testing

Environment Testing

Electronics Testing

0.9

0.6

0.4

13.4

0.5

0.2

6.8

2021 | 2030

2022 | 2027

2021 | 2026

2021 | 2028

Factors Driving Industry Growth

Drug Discovery & Development

Food Testing

Electrical & Electronics Testing

Environment Testing

Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry

Specialized knowledge, skills and testing tools that CROs can provide

Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing

Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives

Green push by Government for electrical vehicles

Increase in regulations to address the growing concerns of air, water and soil contamination

Our Competitive Advantage

Our Position in the CRTO Landscape Our Strength

Our Position in the CRTO Landscape

Pharma Analytical

#1 in India

Customers – 90% of India top 20

36% revenues from overseas

Food Testing

#1 in India

Serving 7 of India’s top 10 food companies

The only private EU commission approved lab in India

Clinical Research

Preclinical

Among the most reputed CROs in India

Amongst Top 5 in India

75% of revenues from overseas

Electronics & Electricals

Start-up

Environment

Among top 5 in India

Customers – PSUs, large corporations across industries

Our Strengths

Infrastructure

Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium

Customer Centricity

Long term partnerships with customers

Compliance

Strong culture of quality and compliance

Long & successful regulatory track record – cGMP, GLP, GCP

Compliance

Innovations

Strong culture of quality and compliance

Continuous addition of services and evolving excellence

Knowledge

Multi-disciplinary, knowledgeable, skilled and trained manpower

Technology

Wide range of state-of-the-art technologies and scalable capacities

Way Forward

Our Key Growth Drivers & Strategies

Our Key Growth Drivers & Strategies

Favourable markets

Core business strategies

 Growth momentum

in markets

 Growing demand

for safe & quality - drugs, food, diagnostics, electronics & clean environment

 Capacity expansions

 Service innovations

 Penetration into new markets

 Customer partnerships

Core operational strategies

 Operational excellence

 Hiring right talent

Best practices

 Good corporate governance

 Risk management

 Quality & compliance culture

 Listening to customers’ needs

 Cutting edge technologies

 Continuous learning

We aspire to reach revenues of >Rs.500 cr by 2025/26

31 31

Thank You

Vimta Labs Ltd.

Chief Financial Officer

Siva Rama Krishna Kambhampati Siva.Kambhampati@vimta.com

Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.Bhadekar@in.ey.com

Registered Office Plot

NSE: VIMTALABS

Plot #142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051

BSE: 524394

ISIN: INE579C01029

Website: www.vimta.com

PTTT 32

← All Transcripts VIMTALABS Stock Page →

Vimta Labs Limited has informed the Exchange about Investor Presentation

Market Movers